Pulse.

a daily field guide to health research that matters

◆ Console

‹ Fri · 6 Nov 2026
Promising but preliminary

Soxataltinib, a highly selective CNS-penetrant RET inhibitor demonstrates durable activity in RET fusion-positive non-small cell lung cancer phase 2 study.

A highly selective RET inhibitor shows promising activity against brain tumors in lung cancer, pending direct comparison with existing treatments.

A phase 2 study evaluated the CNS-penetrant RET inhibitor soxataltinib in RET fusion-positive non-small cell lung cancer. The 84.8% response rate and observed intracranial activity are clinically promising, but the single-arm design requires comparative confirmation.

What the study was

Study design
Single-arm phase 2 clinical trial
Population
Patients with RET fusion-positive non-small cell lung cancer
Category
Treatment Innovation
Maturity
Validated
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Why it surfaced

Strong phase 2 response data in a molecularly defined cancer population merit high-priority downstream review despite the absence of a randomized comparator.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.